CVS Health reports Q2 2025 results and updates guidance

Details

GAAP diluted EPS was $0.80, down from $1.41 due to litigation charges. Adjusted EPS remained stable at $1.81. The company updated its full-year 2025 guidance, raising the Adjusted EPS range to $6.30 to $6.40 and the cash flow from operations guidance to at least $7.5 billion.

Items reported

Exhibits (1)

About CVS Health Corporation

CVS Health Corporation is a leading health services company in the United States, offering a comprehensive range of services aimed at improving healthcare accessibility and convenience. Primarily known for its extensive network of pharmacies, CVS Health operates thousands of retail locations nationwide. These outlets provide prescription medications, over-the-counter drugs, health and wellness products, and immunization services. Beyond retail, CVS Health plays a significant role in the healthcare sector through its pharmacy benefit management division, Caremark, which administers prescription drug plans for insurers and employers. Additionally, the company owns Aetna, a major health insurance provider, aligning its services across retail, pharmacy benefits, and insurance solutions to deliver integrated healthcare experiences. With its broad reach and diverse healthcare offerings, CVS Health Corporation holds a critical place in the healthcare market, continuously working to streamline and enhance the delivery of medical services across the country.